GLYCOPYRRONIUM\INDACATEROL: 2,113 Adverse Event Reports & Safety Profile
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
2,113
Total FAERS Reports
373 (17.7%)
Deaths Reported
849
Hospitalizations
2,113
As Primary/Secondary Suspect
94
Life-Threatening
61
Disabilities
First Report: 1995 · Latest Report: 20241001
What Are the Most Common GLYCOPYRRONIUM\INDACATEROL Side Effects?
#1 Most Reported
Dyspnoea
400 reports (18.9%)
#2 Most Reported
Chronic obstructive pulmonary disease
291 reports (13.8%)
#3 Most Reported
Cough
232 reports (11.0%)
All GLYCOPYRRONIUM\INDACATEROL Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Dyspnoea | 400 | 18.9% | 38 | 219 |
| Chronic obstructive pulmonary disease | 291 | 13.8% | 36 | 188 |
| Cough | 232 | 11.0% | 8 | 96 |
| Pneumonia | 205 | 9.7% | 30 | 167 |
| Wheezing | 203 | 9.6% | 2 | 142 |
| Lung neoplasm malignant | 138 | 6.5% | 16 | 77 |
| Oedema peripheral | 130 | 6.2% | 4 | 83 |
| Death | 126 | 6.0% | 126 | 12 |
| Malaise | 119 | 5.6% | 8 | 52 |
| Gastrooesophageal reflux disease | 114 | 5.4% | 0 | 77 |
| Product use issue | 114 | 5.4% | 19 | 39 |
| Bronchiectasis | 113 | 5.4% | 1 | 77 |
| Rhinitis allergic | 109 | 5.2% | 0 | 76 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 108 | 5.1% | 0 | 75 |
| Condition aggravated | 108 | 5.1% | 8 | 90 |
| Nasal polyps | 107 | 5.1% | 0 | 74 |
| Total lung capacity increased | 107 | 5.1% | 0 | 74 |
| Cardiac murmur | 106 | 5.0% | 0 | 73 |
| Sarcoidosis | 106 | 5.0% | 0 | 73 |
| Vomiting | 104 | 4.9% | 10 | 80 |
Who Reports GLYCOPYRRONIUM\INDACATEROL Side Effects? Age & Gender Data
Gender: 44.3% female, 55.7% male. Average age: 68.8 years. Most reports from: COUNTRY NOT SPECIFIED. View detailed demographics →
Is GLYCOPYRRONIUM\INDACATEROL Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 5 | 0 | 0 |
| 2002 | 2 | 1 | 1 |
| 2006 | 2 | 0 | 0 |
| 2011 | 1 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 11 | 2 | 7 |
| 2014 | 181 | 41 | 77 |
| 2015 | 282 | 42 | 124 |
| 2016 | 258 | 41 | 85 |
| 2017 | 84 | 30 | 49 |
| 2018 | 28 | 2 | 16 |
| 2019 | 44 | 7 | 22 |
| 2020 | 76 | 16 | 27 |
| 2021 | 97 | 12 | 41 |
| 2022 | 54 | 8 | 15 |
| 2023 | 33 | 3 | 16 |
| 2024 | 7 | 0 | 4 |
What Is GLYCOPYRRONIUM\INDACATEROL Used For?
| Indication | Reports |
|---|---|
| Chronic obstructive pulmonary disease | 1,106 |
| Product used for unknown indication | 642 |
| Asthma | 95 |
| Emphysema | 73 |
| Respiratory disorder | 42 |
| Lung disorder | 33 |
| Dyspnoea | 24 |
| Bronchitis | 15 |
| Depression | 11 |
| Malignant melanoma | 11 |
GLYCOPYRRONIUM\INDACATEROL vs Alternatives: Which Is Safer?
GLYCOPYRRONIUM\INDACATEROL vs GOLD
GLYCOPYRRONIUM\INDACATEROL vs GOLD THIOMALATE
GLYCOPYRRONIUM\INDACATEROL vs GOLIMUMAB
GLYCOPYRRONIUM\INDACATEROL vs GOLODIRSEN
GLYCOPYRRONIUM\INDACATEROL vs GONADORELIN
GLYCOPYRRONIUM\INDACATEROL vs GONADOTROPHIN, CHORIONIC
GLYCOPYRRONIUM\INDACATEROL vs GOSERELIN
GLYCOPYRRONIUM\INDACATEROL vs GRAMICIDIN
GLYCOPYRRONIUM\INDACATEROL vs GRAMICIDIN\NEOMYCIN\POLYMYXIN B
GLYCOPYRRONIUM\INDACATEROL vs GRAMICIDIN\POLYMYXIN B
Official FDA Label for GLYCOPYRRONIUM\INDACATEROL
Official prescribing information from the FDA-approved drug label.